MEDICINOVA INC Income Statement
MNOV|9 years of annual SEC 10-K data (FY2011-FY2025)
Line items include revenue, cost of goods sold, gross profit, operating expenses, interest, taxes, and net income with per-share data across 9 fiscal years. All figures from audited SEC 10-K filings.
MEDICINOVA INC reported $409,657 in revenue and $12M in net loss for FY2025. Revenue has declined at a 9.1% compound annual rate over the past 14 years.
Based on SEC 10-K filings.
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -4.27 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2014 | FY2013 | FY2012 | FY2011 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $409.7K | $1.0M | $1.0M | - | $4.0M | - | $3.0K | $191.0K | $1.6M |
| Cost of Revenue | - | - | - | - | - | - | - | $1.3M | $1.3M |
| SG&A Expense | $6.2M | $5.2M | $5.5M | $5.5M | $5.7M | $6.0M | $6.7M | $8.3M | $8.3M |
| R&D Expense | $6.7M | $5.3M | $8.7M | $8.7M | $8.1M | $2.9M | $4.5M | $7.8M | $7.8M |
| Operating Income | -$13.3M | -$9.9M | -$14.6M | -$14.6M | -$10.2M | -$9.2M | -$10.9M | -$16.1M | -$16.1M |
| Interest Expense | - | - | - | - | - | $628 | - | $1.6M | $1.6M |
| Income Tax | $6.0K | $3.0K | $2.8K | $2.8K | $2.6K | -$4.0K | $11.1K | $11.6K | $11.6K |
| Net Income | -$12.0M | -$8.6M | -$14.1M | -$14.1M | -$10.1M | -$9.2M | -$11.0M | -$25.7M | -$17.7M |
| EPS (Basic) | -$0.23 | -$0.17 | -$0.29 | -$0.21 | - | - | -$0.14 | - | - |
| EPS (Diluted) | -$0.23 | -$0.17 | -$0.29 | -$0.21 | -$0.31 | -$0.19 | -$0.14 | -$1.20 | -$1.68 |
| Shares Outstanding | 49.0M | 49.0M | 49.0M | 49.0M | 45.0M | 22.5M | 17.4M | 16.1M | 12.4M |
| Operating Margin | -3242.5% | -990.0% | -1462.9% | - | -253.0% | - | -364845.2% | -8433.7% | -1033.8% |
| Profit Margin | -2928.8% | -857.2% | -1406.9% | - | -251.0% | - | -365377.1% | -13451.4% | -1138.1% |